Autl stock

Who buys Autolus shares?Several institutional investors purchased shares in AUTL during the quarter, including Pendal Group Ltd, Cetera Investment Advisors, BlackRock Inc., MYDA Advisors LLC, Citadel Advisors LLC, GSA Capital Partners LLP, Jump Financial LLC and Brighton Jones LLC. How can I buy shares of Autolus Therapeutics?

What is Autolus Therapeutics'(ATR) stock price potential in the next year?

Your forecast varies between $ and $. In this case, Autolus Therapeutics will add $ to the selected status. This could lead to a rise in share prices.

What is the upside for Autolus Therapeutics'stock?

Your forecast varies between $ and $. On average, they expect Autolus Therapeutics' stock price to hit 0 next year. This indicates a possible rise in the current share price. View analyst price targets for major stocks from Autolus Therapeutics or Wall Street analysts.

Who is buying autolus stock today

Shares of Autolus Therapeutics (NASDAQ:AUTL) rose 25% Monday after the biopharmaceutical company reached an agreement to provide up to 0 million in funding from Blackstone Life Sciences. As part of the deal, Blackstone agreed to buy shares of US custodian Autolus for 0 million.

What does the Blackstone-Autolus deal mean for Autolus?

Under the terms of the deal, Blackstone agreed to purchase a 0 million US equity trust from Autolus. In addition, Autolus will receive an initial payment of million and 0 million in milestone payments.

Who is buying autolus stock 2020

Of the 68 institutional investors who bought Autolus Therapeutics shares in the past 24 months, the following investors and hedge funds bought the most shares: Citadel Advisors LLC ($), Frazier Management LLC ($), Schroder Investment Management Group ($$), Opaleye Management Inc. ($), Deerfield Management Company Series C ($), Nantahala Capital Management LLC ($), and Capital International Investors ($).

What are analysts'target prices for Autolus Therapeutics'stock?

Eight brokers have set annual target prices for Autolus Therapeutics stock. Your prediction is between $ and $. On average, they expect Autolus Therapeutics' stock price to hit 0 in the next 12 months. This indicates a possible rise in the current share price.

What is the ticker symbol for Autolus Therapeutics?

Autolus Therapeutics is listed on NASDAQ under the symbol AUTL. Who are the main shareholders of Autolus Therapeutics? Autolus Therapeutics stocks are owned by many retail and institutional investors.

Who owns autautolus Therapeutics'stock?

Autolus Therapeutics stocks are owned by many retail and institutional investors. Major institutional investors are Pendal Group Ltd (), Millennium Management LLC (), Eversept Partners LP (), Morgan Stanley (), Granahan Investment Management Inc. MA () and MYDA Advisors LLC ().

Who is buying autolus stock now

Blackstone buys AUTL shares for 0 million. This will be done through a private placement, the exact details of which are not yet known. Blackstone's investment in Autolus Therapeutics has another benefit. This gives BX the right to appoint a member of the board of directors of the company.

What is the upside for Autolus Therapeutics'share price?

On average, they expect Autolus Therapeutics' stock price to hit the dollar over the next 12 months. This indicates a possible rise in the current share price. See analysts' price targets for Autolus Therapeutics.

Which institutional investors are selling Autolus stock?

Several institutional investors sold AUTL stock during the quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Granahan Investment Management Inc. MA, Morgan Stanley, Eversept Partners LP, UBS Group AG and Lindbrook Capital LLC. Which Institutional Investors Are Buying Autolus Therapeutics Shares?

Who is buying autolus stock market

Blackstone buys AUTL shares for 0 million. This will be done through a private placement, the exact details of which are not yet known. Blackstone's investment in Autolus Therapeutics has another benefit.

Why did Autolus Therapeutics plc jump 30% in premarket Monday?

Promotions Autoloop TherapeuticsAnonymous society(NASDAQ:AUTL) rose about 30% in premarket trading Monday after it was announced that Blackstone Life Sciences had agreed to invest up to 0 million to fund the expansion.

Why did Blackstone invest $250 million in Autolus Therapeutics?

Blackstone Inc. invests up to 0 million in biotech company Autolus Therapeutics PLC to fund the final stages of development of a new treatment for severe leukemia, demonstrating progress in the company's commercial manufacturing process and based on positive clinical data from Obecel, presented at the EHA.

What does Autolus Therapeutics plc (ATC) do?

Sign up for the FREE daily MarketBeats newsletter to receive the latest news and reviews from Autolus Therapeutics and its competitors. Autolus Therapeutics Plc is a biopharmaceutical company engaged in the development and commercialization of gene therapy.

What is the upside for autolus therapeutics&#39 stock analysis

Analysts say shares of Autolus Therapeutics are likely to rise based on 12-month price targets. Which Analysts Cover Autolus Therapeutics? Autolus Therapeutics has been validated by HC Wainwright in the last 90 days. This page was last updated by the staff on 01/13/2022

What are analysts'forecasts for Autolus Therapeutics'stock's price?

Six brokers have posted 12-month price targets for shares of Autolus Therapeutics. Your forecast varies between $ and $. On average, they expect Autolus Therapeutics' stock price to hit 0 next year. This indicates a possible rise in the current share price.

Autl stock forecast

AUTL Futures Forecast According to CNN Business, 9 different analysts predict that AUTL stocks will remain bullish for the next 12 months. Based on the forecast, AUTL has an average dollar target of $ and no higher than $.

Autl stock price target

These are more reasonable unconscious decisions. Disclaimer: Analytical information is for informational purposes and news agencies only.

Did Autolus Therapeutics insiders sell or buy the stock?

Autolus Therapeutics experts have not bought or sold any shares of the company in the past three months. The institutions own a portion of the shares of Autolus Therapeutics. Shares of Autolus Therapeutics are expected to fall from ($) to ($) per share over the next year.